Mads Krogsgaard Thomsen
Executive vice president, head of R&D and chief science officer (CSO)
Mads Krogsgaard Thomsen joined Novo Nordisk in 1991 as head of Growth Hormone Research. He was appointed senior vice president of Diabetes R&D in 1994 and in November 2000 he was appointed executive vice president and chief science officer. In this role, he is responsible for global drug and device research, CMC and global development, medical affairs, regulatory and safety within Novo Nordisk.
Mads Krogsgaard Thomsen serves as member of the board of Symphogen A/S, Denmark, and of BB Biotech AG, Switzerland. He is also a member of the editorial boards of international, peer-reviewed journals. Mads Krogsgaard Thomsen has also been serving as an adjunct professor at the Royal Veterinary and Agricultural University (now the Faculty of Health and Medical Sciences of the University of Copenhagen) since 2000.